14 October 2021  
EMA/CHMP/584205/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion 1 (post authorisation) 
Repatha 
evolocumab 
On 14 October 2021, the Committee for Medicinal Products for Human  Use (CHMP)  adopted a positive 
opinion recommending a change to  the terms of the marketing authorisation for the medicinal product 
Repatha. The marketing authorisation holder for this medicinal product is Amgen Europe B.V. 
The CHMP adopted a change to the  indication as follows: 2 
Hypercholesterolaemia and mixed dyslipidaemia 
Repatha is indicated in  adults with  primary hypercholesterolaemia (heterozygous familial and 
non-familial) or mixed dyslipidaemia, and in paediatric patients  aged 10 years and  over 
with heterozygous familial hypercholesterolaemia,  as an adjunct  to diet: 
•
•
in combination with  a statin or statin  with other lipid-lowering therapies in patients unable to
reach LDL-C goals with  the maximum tolerated dose of a statin or,
alone or in combination with  other lipid-lowering therapies in  patients who are statin-
intolerant, or for whom a statin  is contraindicated.
Homozygous familial hypercholesterolaemia 
Repatha is indicated in  adults and adolescents paediatric patients  aged 12 10 years and over 
with  homozygous familial hypercholesterolaemia in combination with other lipid-lowering 
therapies. 
Established atherosclerotic cardiovascular disease 
Repatha is indicated in  adults with  established atherosclerotic cardiovascular disease (myocardial 
infarction, stroke or peripheral arterial disease) to  reduce cardiovascular risk by lowering LDL-C 
levels, as an adjunct to correction of other risk factors: 
•
in combination with  the maximum tolerated dose of a statin  with  or without  other lipid-
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European  Union  
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
lowering therapies or, 
• 
alone or in combination with  other lipid-lowering therapies in  patients who are statin-
intolerant, or for whom a statin  is contraindicated. 
Detailed recommendations for the use of this  product will be described in the updated summary of 
product characteristics (SmPC), which will  be published in the  revised European public assessment report 
(EPAR), and will be available in all official European Union  languages after a decision on this change to 
the marketing authorisation has been granted by the  European Commission. 
Repatha  
EMA/CHMP/584205/2021 
Page 2/2 
 
 
 
